MORAb-202
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for MORAb-202, covering 2025-07-03 to 2026-03-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types [Phase 1, Phase 2]